SCHEMBL25327355

SCHEMBL25327355

CCOC(=O)c1c(F)ccn1NC(=O)NC(=O)C(Cl)(Cl)Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
CASP3 P42574 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
TP53 P04637 2/20 0.35
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34
JMJD6 Q6NYC1 1/20 0.34
TSHR P16473 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25326725 0.78 LMNA (0.41) KMT2AMAPTMEN1CASP3TRPV1
SCHEMBL25327703 0.74 MAPK14 (0.33) ALDH1A1
SCHEMBL25327014 0.72 SMN1; SMN2 (0.48) KMT2AMAPTMEN1ALDH1A1GAA
SCHEMBL16236650 0.69 MAPT (0.45) KMT2AMAPTMEN1CASP3TRPV1
SCHEMBL22149804 0.68 LMNA (0.46) KMT2AMAPTMEN1CASP3TRPV1
SCHEMBL25327020 0.67 MEN1 (0.39) KMT2AMAPTMEN1TP53TSHR
SCHEMBL25361763 0.66 ALDH1A1 (0.40) KMT2AMAPTTSHRALDH1A1GAA
SCHEMBL28964869 0.66 SMN1; SMN2 (0.43) KMT2AMAPTMEN1CASP3TRPV1
SCHEMBL25610744 0.66 ALDH1A1 (0.42) KMT2AMAPTMEN1CASP3TRPV1
SCHEMBL29977115 0.65 TDP1 (0.36) KMT2AMAPTMEN1CASP3TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163063-A1 INHIBITORS OF CDK4/6 KINASE KHORA SPV 1, LLC 2025-05-22 US disclosed
EP-4469062-A1 INHIBITORS OF CDK4/6 KINASE Kinnate Biopharma Inc. (US) 2024-12-04 EP disclosed
WO-2023147372-A1 INHIBITORS OF CDK4/6 KINASE KINNATE BIOPHARMA INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163063-A1 INHIBITORS OF CDK4/6 KINASE CDK4, CDK6, CDK2 KMT2A 851/4885MAPT 2056/4885MEN1 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.